Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23138507 | 0.87 | RAB9A (0.45) | SMN1; SMN2POLBALDH1A1RAB9AMAPT | |
| SCHEMBL19451723 | 0.83 | ALDH1A1 (0.45) | SMN1; SMN2POLBTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL6188814 | 0.83 | MAPT (0.52) | SMN1; SMN2POLBTDP1ALDH1A1RAB9A | |
| SCHEMBL18718147 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2POLBTDP1ALDH1A1RAB9A | |
| SCHEMBL18718164 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2POLBTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL1198071 | 0.79 | LMNA (0.58) | SMN1; SMN2POLBTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL13170000 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBTDP1L3MBTL1ALDH1A1 | |
| SCHEMBL19617291 | 0.78 | SMN1; SMN2 (0.43) | SMN1; SMN2POLBTDP1ALDH1A1RAB9A | |
| SCHEMBL23138330 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2POLBTDP1ALDH1A1RAB9A | |
| SCHEMBL2355085 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2POLBTDP1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114981273-B | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国科学院上海药物研究所 | 2024-03-01 | — | — | CN | disclosed |
| US-20220389025-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-12-08 | — | — | US | disclosed |
| CN-112521371-B | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-114981273-A | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method and application thereof | 中国科学院上海药物研究所 | 2022-08-30 | — | — | CN | disclosed |
| EP-4032890-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-07-27 | — | — | EP | disclosed |
| CN-112521371-A | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2021-03-19 | — | — | CN | disclosed |
| CN-112521394-A | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2021-03-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389025-A1 | HETEROCYCLIC AMIDE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | STING1, CGAS, MYD88 | SMN1; SMN2 2965/4885POLB 3461/4885TDP1 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.